publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
bronchiol
number
one
caus
hospit
infant
first
year
life
clinic
guidelin
recom
mend
primarili
support
care
discourag
use
pharmacotherapi
diagnost
howev
con
tinu
widespread
use
nonrecommend
therapi
variat
use
therapeut
intervent
among
hospit
unit
state
review
evidencebas
man
agement
common
diseas
order
optim
resourc
util
decreas
healthcar
cost
de
creas
unnecessari
hospit
current
evid
support
routin
use
chest
radiograph
viral
test
laboratori
evalu
chil
dren
bronchiol
addit
rou
tine
administr
bronchodil
includ
albuterol
nebul
epi
nephrin
corticosteroid
hyperton
salin
recommend
infant
children
bronchiol
intrav
nou
nasogastr
hydrat
nutri
tional
support
supplement
oxygen
respiratori
support
recom
mend
standard
bronchiol
care
evid
base
institut
clinic
pathway
span
ed
inpa
tient
care
help
optim
resourc
util
simultan
improv
ing
care
bronchiol
reduc
hospit
length
stay
cost
bronchiol
number
one
caus
hospit
infant
first
year
life
clinic
guidelin
recom
mend
primarili
support
care
discourag
use
pharmacotherapi
diagnost
howev
con
tinu
widespread
use
nonrecommend
therapi
variat
use
therapeut
intervent
among
hospit
unit
state
review
evidencebas
man
agement
common
diseas
order
optim
resourc
util
decreas
healthcar
cost
de
creas
unnecessari
hospit
current
evid
support
routin
use
chest
radiograph
viral
test
laboratori
evalu
chil
dren
bronchiol
addit
rou
tine
administr
bronchodil
includ
albuterol
nebul
epi
nephrin
corticosteroid
hyperton
salin
recommend
infant
children
bronchiol
intrav
nou
nasogastr
hydrat
nutri
tional
support
supplement
oxygen
respiratori
support
recom
mend
standard
bronchiol
care
evid
base
institut
clinic
pathway
span
ed
inpa
tient
care
help
optim
resourc
util
simultan
improv
ing
care
bronchiol
reduc
hospit
length
stay
cost
b
ronchiol
number
one
caus
hospit
infant
first
month
life
result
approxim
hospit
admiss
annual
unit
state
translat
estim
cost
billion
direct
medic
cost
exceed
million
clinic
guidelin
recommend
primarili
support
care
discourag
use
pharmacotherapi
diagnost
improv
outcom
howev
continu
wide
variabl
hospitalbas
care
bronchiol
among
us
intern
institut
given
high
financi
medic
burden
bronchiol
famili
healthcar
facil
prudent
continu
review
evid
base
manag
common
diseas
order
optim
resourc
util
decreas
healthcar
cost
decreas
unnecessari
hospit
background
pathogenesi
bronchiol
viral
ill
occur
children
age
year
character
upper
respiratori
prodrom
follow
lower
respiratori
tract
infect
viru
infect
termin
bronchiolar
epithelium
cell
caus
edema
excess
mucou
epitheli
slough
result
obstruct
atelectasi
small
airway
viru
induc
wheez
acut
viraltrigg
asthma
may
overlap
clinic
syndrom
bronchiol
young
children
incid
bronchiol
typic
highest
novemb
march
region
variat
multipl
virus
infect
lower
respiratori
tract
caus
clinic
syndrom
bronchiol
respiratori
syncyti
viru
rsv
far
common
etiolog
respons
bronchiol
case
age
year
children
infect
rsv
contract
lower
respiratori
tract
infect
reinfect
rsv
com
mon
sinc
primari
infect
confer
immun
rhinoviru
second
com
mon
viral
pathogen
caus
bronchiol
associ
recurr
wheez
less
common
etiolog
includ
influenza
human
metapneumoviru
coronaviru
parainfluenza
ad
enoviru
human
bocaviru
one
third
children
hospit
bronchiol
coinfect
two
virus
risk
factor
complic
sever
diseas
includ
age
less
week
prematur
gestat
age
b
week
underli
hemodi
namic
signific
cardiopulmonari
diseas
immunodefici
anatom
defect
airway
neurolog
diseas
infant
young
children
bronchiol
typic
present
prodrom
fever
cough
congest
rhinorrhea
follow
lower
respiratori
tract
involv
lower
respiratori
tract
involv
manifest
tachypnea
wheez
ing
rale
increas
respiratori
effort
evi
denc
retract
nasal
flare
accessori
muscl
use
grunt
diagnosi
bronchi
oliti
base
primarili
histori
physic
present
routin
includ
imag
lab
diagnost
persist
increas
respiratori
effort
sever
tachypnea
hypoxemia
apnea
intoler
feed
may
warrant
hospit
assess
sever
manag
decis
complic
variabl
exam
find
time
evid
relat
specif
clinic
find
outcom
limit
mani
attempt
creat
object
clinic
score
system
sever
assess
base
clinic
evalu
widespread
adopt
one
system
due
lack
valid
predict
valu
addit
known
risk
factor
sever
diseas
effect
respiratori
symptom
feed
hydrat
mental
statu
also
assess
consid
hospit
current
evid
support
routin
use
chest
radiograph
children
bronchi
oliti
need
diagnos
bronchiol
alter
clinic
cours
lead
unnecessari
antibiot
use
chest
radiograph
reserv
patient
physic
exam
find
suggest
altern
diagnosi
concern
foreign
bodi
vascular
ring
undiagnos
cardiac
diseas
etc
present
particularli
sever
featur
bronchiol
chest
radiograph
nonspecif
often
patchi
segment
atelec
tasi
peribronchi
thicken
find
often
interpret
develop
pneumonia
lead
unnecessari
antibiot
use
particularli
patient
mild
moder
diseas
nine
year
prospect
studi
children
hospi
taliz
rsv
percent
develop
subsequ
bacteri
pneumonia
obtain
chest
radiograph
warrant
present
sever
diseas
requir
intens
care
unit
icu
admiss
mechan
ventil
patient
increas
risk
develop
com
plicat
secondari
bacteri
pneumonia
pneumomediastinum
pneumothorax
laboratori
diagnost
viral
polymeras
chain
reaction
pcr
test
routin
recommend
clear
benefit
determin
exact
viral
etiolog
pcr
patient
known
bronchiol
may
potenti
benefit
viral
pcr
unclear
clinic
pictur
sever
present
multipl
diagnos
consid
child
receiv
monthli
prophylaxi
palivizu
mab
present
bronchiol
viral
pcr
perform
determin
rsv
etiolog
agent
posit
rsv
find
warrant
discontinu
ation
prophylaxi
given
low
likelihood
repeat
infect
rsv
year
secondari
bacteri
infect
uncommon
children
bronchiol
except
acut
otiti
media
one
nine
year
prospect
studi
involv
patient
rsv
bronchiol
demonstr
subsequ
bacteri
infect
kind
studi
shown
febril
infant
distinct
viral
syndrom
ie
bronchiol
risk
secondari
bacteri
infect
blood
cerebrospin
fluid
csf
less
percent
system
review
seriou
bacteri
infect
febril
hospit
infant
age
day
confirm
extrem
rariti
bacteremia
csf
infect
found
rate
urinari
tract
infect
find
support
prospect
studi
suggest
routin
evalu
seriou
bacteri
infec
tion
complet
blood
count
urinalysi
urin
cul
ture
blood
cultur
csf
studi
febril
infant
age
day
diagnosi
bronchiol
unjustifi
american
academi
pediatr
aap
along
multipl
similar
intern
group
recommend
use
evid
base
support
ther
api
manag
bronchiol
includ
intraven
iv
nasogastr
ng
hydrat
nutrit
support
supplement
oxygen
respiratori
support
tabl
infant
young
children
bronchiol
increas
insens
loss
fever
tachypnea
well
decreas
intak
due
congest
tachypnea
respiratori
distress
respiratori
rate
exceed
breath
per
minut
worsen
sign
respiratori
distress
feed
retract
nasal
flare
may
creas
risk
aspir
oral
hydrat
maintain
due
tachypnea
increas
work
breath
iv
ng
fluid
administ
signific
differ
efficaci
safeti
includ
advers
event
icu
admiss
need
mechan
ventil
hospit
length
stay
lo
infant
given
intraven
hydrat
compar
nasogastr
hydrat
howev
infant
moder
sever
respira
tori
distress
respiratori
rate
global
retrac
tion
cyanosi
apnea
requir
respiratori
support
mainstay
bronchiol
manag
may
includ
nasal
suction
supplement
oxygen
high
flow
nasal
cannula
hfnc
continu
posit
airway
pressur
cpap
mechan
ventil
suction
nasopharynx
salin
infant
bronchiol
common
practic
improv
upper
airway
obstruct
caus
nasal
congest
thu
improv
infant
abil
feed
retrospect
cohort
studi
infant
age
month
hospit
bronchiol
deep
nasal
suction
cathet
actual
associ
longer
hospit
lo
possibl
due
trauma
mucos
edema
interestingli
studi
note
longer
lo
greater
hour
laps
noninvas
extern
nasal
suction
current
data
suggest
frequent
noninvas
nasal
suction
benefici
clinic
cours
bronchiol
routin
deep
suction
nasopharyng
cathet
may
benefici
frequent
cathet
suction
infant
deem
sever
present
may
confound
futur
prospect
random
trial
nasal
suction
may
help
clarifi
data
supplement
oxygen
via
nasal
cannula
use
infant
young
children
unabl
maintain
oxyhemoglobin
satur
set
bronchiol
puls
oximet
spo
accuraci
reflect
arteri
partial
pressur
oxygen
sao
poor
accur
within
sao
read
base
oxyhemoglobin
dissoci
curv
spo
less
increment
increas
sao
associ
signific
improv
spo
spo
greater
increas
requir
much
larger
elev
sao
despit
poor
predictor
respiratori
distress
oxygen
satur
drive
clinic
factor
hospit
admiss
ed
subsequ
hospit
lo
import
weigh
risk
hypoxemia
risk
hospit
transient
hypox
emia
common
healthi
infant
though
chronic
hypoxemia
associ
development
behavior
problem
issu
born
otherwis
healthi
children
experi
enc
intermitt
hypoxemia
temporari
diseas
state
carbon
dioxid
concentr
blood
greater
impact
respiratori
drive
oxygen
satur
respiratori
distress
poorli
correl
oxygen
satur
infant
cyanosi
clinic
sign
accur
identifi
hypoxemia
infant
children
consid
discharg
home
close
follow
children
spo
present
mild
moder
diseas
vigor
maintain
oral
hydrat
minim
sign
respiratori
distress
children
worsen
respiratori
distress
progress
respiratori
failur
benefit
non
invas
ventil
hfnc
cpap
use
mitig
respiratori
effort
improv
ga
exchang
avoid
intub
deterior
child
bronchiol
avoid
possibl
advers
effect
intub
laryng
nerv
injuri
sub
glottic
stenosi
ventil
associ
pneumonia
narcot
withdraw
sedat
clear
benefit
hfnc
typic
util
first
follow
cpap
attempt
avoid
intub
hfnc
provid
combin
fio
posit
end
expiratori
pressur
cm
h
flow
shown
reduc
respiratori
effort
recent
prospect
studi
look
optim
flow
rate
demonstr
signific
im
provement
respiratori
effort
children
bronchiol
lkgminut
hfnc
esp
cialli
infant
kg
hfnc
also
improv
ga
exchang
wash
co
pulmonari
dead
space
decreas
rate
intub
mechan
ventil
particularli
strong
retrospect
studi
australia
evalu
infant
bronchiol
show
decreas
intub
rate
introduct
hfnc
hfnc
associ
avoid
icu
admiss
recent
random
trial
children
age
year
age
moder
sever
bronchiol
receiv
either
earli
initi
hfnc
nasal
cannula
earli
initi
hfnc
also
found
import
observ
studi
reveal
associ
hfnc
failur
low
pretreat
ph
high
pretreat
pco
infant
persist
sever
worsen
respiratori
statu
despit
hfnc
cpap
may
requir
intub
mechan
ventil
sign
impend
respiratori
failur
includ
mark
global
retract
nasal
flare
head
bob
diminish
absent
breath
sound
fatigu
bradypnea
hypoxemia
despit
supplemen
tal
oxygen
weak
cri
decreas
respons
stimul
hypercapnea
typic
present
blood
ga
inform
util
conjunct
rest
clinic
pictur
decid
whether
intub
infant
bronchiol
despit
evid
support
therapi
mainstay
bronchiol
manag
routin
recommend
use
major
us
intern
guidelin
continu
signific
interhospit
intern
variat
treatment
time
studi
pediatr
emerg
research
network
pern
matter
demonstr
infant
hospit
bronchiol
receiv
evid
base
support
therapi
emerg
depart
visit
inpati
hospitali
zation
recent
guidelin
regard
bronchiol
iti
manag
includ
aap
clinic
guidelin
consist
clinic
benefit
shown
use
adrenerg
agent
random
ize
control
studi
bronchodil
may
improv
clinic
symptom
score
shortterm
improv
overal
outcom
need
lo
hospit
hospit
moreov
clinic
symptom
score
valid
measur
efficaci
correl
object
measur
pulmonari
function
test
subject
interus
variabl
albuterol
cochran
systemat
review
albuterol
use
bronchiol
demonstr
potenti
advers
effect
increas
cost
care
without
clear
clinic
benefit
review
assess
bronchodil
use
oxygen
satur
random
control
trial
includ
children
countri
heterogen
studi
significantli
duce
sensit
analysi
overal
review
show
benefit
studi
show
benefit
weaker
methodolog
includ
older
children
histori
recurr
wheez
logic
argument
made
subset
infant
children
ie
recurr
wheez
histori
eczema
bronchiol
may
revers
airway
obstruct
smooth
muscl
constrict
would
benefit
albuterol
cochran
review
chavess
et
al
albuterol
use
children
younger
year
recurr
wheez
find
clear
benefit
agonist
use
popul
subset
review
includ
studi
outpati
set
ed
pulmonari
function
lab
set
current
evid
regard
nebul
epi
nephrin
suggest
use
bronchiol
inpati
set
meta
analysi
hartl
et
al
review
evid
nebul
epinephrin
use
bronchiol
found
evid
support
use
inpati
sever
multicent
random
trial
compar
nebul
epinephrin
placebo
albuterol
placebo
alon
found
lack
efficaci
demonstr
longer
lo
use
fix
schedul
role
nebul
epinephrin
ed
outpati
set
unclear
canadian
bron
chioliti
epinephrin
steroid
trial
multicent
random
trial
involv
patient
ed
compar
hospit
period
adjust
multipl
variabl
chang
need
admiss
day
group
patient
receiv
nebul
epinephrin
plu
oral
dexamethason
compar
group
receiv
nebul
placebo
plu
oral
placebo
addit
hartl
et
al
system
review
bronchodil
found
nebul
epinephrin
use
ed
de
creas
hospit
admiss
day
visit
compar
placebo
decreas
overal
admiss
rate
unlik
albuterol
nebul
epinephrin
administ
home
transient
effect
signific
decreas
progress
ill
subsequ
admiss
rate
limit
evid
support
routin
use
nebul
epineph
rine
ed
set
plan
discharg
patient
home
howev
trial
includ
children
sever
diseas
respiratori
failur
make
difficult
gener
recom
mendat
bronchodil
use
specif
clinic
scenario
recent
studi
show
administr
bronchodil
ed
creas
increas
age
increas
likelihood
present
recurr
wheez
decreas
oxygen
satur
increas
respiratori
rate
worsen
retract
trial
albuterol
nebul
epinephrin
rescu
agent
sever
diseas
may
warrant
studi
evalu
ate
use
effect
bronchodil
admin
ister
purpos
need
recent
pern
studi
suggest
decreas
use
nonrecommend
intervent
rate
bronchodil
use
declin
rate
chest
radiograph
declin
howev
still
remain
significantli
high
rate
use
nonrecommend
therapi
wide
variat
use
therapeut
interven
tion
among
hospit
us
pern
studi
highlight
variat
intern
scale
confirm
locat
care
regardless
diseas
sever
main
predictor
bronchi
oliti
manag
current
guidelin
recent
find
highlight
import
standard
acut
care
bronchiol
evid
base
pointofcar
clin
ical
practic
pathway
ed
physician
combin
multidisciplinari
institut
pathway
ad
herenc
standard
clinic
practic
pathway
guidelin
associ
reduc
lo
healthcar
cost
strongest
evid
base
recommend
recent
aap
clinic
practic
guidelin
recommend
use
corticosteroid
children
bronchiol
set
cochran
review
trial
includ
larg
edbas
random
trial
patient
show
signific
reduct
hospit
admiss
lo
corticosteroid
compar
placebo
even
young
children
virusassoci
wheez
random
control
trial
shown
oral
steroid
benefici
furthermor
observ
studi
almost
patient
infant
born
week
day
infant
hemodynam
signific
congenit
heart
diseas
infant
cld
requir
fio
least
day
birth
infant
month
cld
still
requir
diuret
chronic
steroid
age
previou
admiss
bronchi
oliti
subsequ
admiss
asthma
find
corticosteroid
use
admiss
bronchiol
associ
improv
outcom
theoret
hyperton
salin
increas
muco
ciliari
clearanc
rehydr
airway
surfac
liquid
howev
cochran
review
trial
inpati
ed
set
show
small
improv
lo
effect
hospit
rate
ed
hyper
tonic
salin
use
subsequ
welldesign
ran
domiz
trial
reiter
lack
effect
hospit
rate
fail
show
improv
ment
hospit
lo
current
evid
support
use
hyperton
salin
bronchiol
ed
inpati
set
palivizumab
monoclon
antibodi
rsv
f
glycoprotein
use
immunoprophylaxi
decreas
risk
hospit
due
sever
rsv
ill
preterm
infant
infant
born
week
day
hemodynami
calli
signific
congenit
heart
diseas
effect
prevent
hospit
acyanot
lesion
chronic
lung
diseas
tabl
prophylaxi
consist
maximum
monthli
dose
mgkgdose
start
rsv
season
caregiv
healthcar
provid
hand
wash
contact
young
children
bronchiol
avoid
contact
other
respiratori
ill
avoid
cigarett
smoke
ex
posur
encourag
breast
feed
least
month
age
shown
reduc
spread
decreas
occurr
sever
bronchiol
current
evid
guidelin
us
intern
recommend
support
therapi
includ
noninvas
nasal
suction
iv
ng
fluid
hydrat
oxygen
support
respiratori
support
manag
bronchiol
inpati
outpati
ed
set
random
control
trial
metaanalys
system
review
support
use
diagno
tic
studi
chest
radiograph
viral
pcr
pharmacotherapi
albuterol
nebul
epineph
rine
corticosteroid
nebul
hyperton
salin
intervent
routin
recommend
standard
bronchiol
care
evid
base
institut
clinic
pathway
span
ed
inpati
care
could
help
optim
resourc
simultan
improv
care
bronchiol
reduc
hospit
lo
cost
